America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the key features of the new cancer treatment drug AOH1996 developed by Dr. Linda Malkas?
**Interview with Dr. Linda Malkas on New Cancer Treatment Breakthrough**
**Editor:** Welcome, Dr. Malkas. Thank you for joining us today. You and your team at City of Hope Hospital have made significant advancements in cancer treatment with your newly developed drug, AOH1996. Can you explain how this drug works?
**Dr. Malkas:** Thank you for having me. AOH1996 is designed to target a specific variant of a protein called PCNA, which plays a crucial role in DNA replication and tumor growth. You can think of PCNA as a large airline terminal, handling all the planes, or in this case, cells that are essential for cancer progression. By disrupting the processes that cancer cells rely on, AOH1996 effectively ‘shuts down’ their growth.
**Editor:** That sounds revolutionary. In your research, what types of cancers have shown the most promise in response to AOH1996?
**Dr. Malkas:** Our studies have shown that AOH1996 is effective against several types of cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We tested this molecule on over 70 different cancer cell lines, and the results indicated selective killing of cancer cells, maintaining the health of normal cells.
**Editor:** Those results are impressive! Can you tell us about the next steps in this research?
**Dr. Malkas:** The next step is to advance our findings into clinical trials with human participants. This phase is critical for determining the drug’s safety and effectiveness in a clinical setting. We’re eager to see how AOH1996 performs in patients and hope to expedite its availability for those in need.
**Editor:** What do you think sets AOH1996 apart from other cancer treatments currently available?
**Dr. Malkas:** AOH1996’s targeted approach allows for more precise treatment of cancer cells without harming normal cells. Traditional chemotherapy often affects both cancerous and healthy cells, leading to severe side effects. Our drug aims to provide a more effective option with potentially fewer side effects, which could significantly improve patients’ quality of life during treatment.
**Editor:** Thank you, Dr. Malkas, for sharing your insights. It’s encouraging to hear about innovations in cancer treatment that could help many people. We’ll be looking forward to the outcomes of your clinical trials.
**Dr. Malkas:** Thank you for the opportunity to discuss our research. We are committed to making advancements in cancer therapy and appreciate your interest.